Final Programme - iuphar

More documents

Recommendations

Info

FC08 Developments in the treatment of sexual dysfunction and diseases of the lower urinary tract Mon 248 The effect of imatinib mesylate on spontaneous activity in the guinea-pig prostate Michelle Lam, (Australia), A Dey, B Exintaris Mon 249 Golgi activation of cdc2 kinase in paclitaxel-inuced apoptosis in human androgen-independent prostate cancers Pin Hsuan Lu, (Taiwan), JH Guh Mon 250 Analysis of cellular signalling for epidermal growth factor-mediated suppression of androgen-induced expression of prostate-specific antigen gene in human prostate cancer LNCaP cells Yuma Maeda, (Japan), R Yamanaka, F Sekiguchi, A Kawabata Mon 251 Effects of fesoterodine 8 mg once daily on the pharmacokinetics and pharmacodynamics of a single supratherapeutic dose of warfarin in healthy subjects Bimal Malhotra, (USA), G Duczynski, C Alvey, J Gong, X Li, K Gandelman 180 Monday 19 July ■ 13:00 - 14:00 ■ Poster Area
FC09 Inflammation and immunopharmacology: New tools for old diseases Mon 252 Effect of chronic mild stress ‘CMS’ on CYP1A2 enzyme activity and inducibility in Wistar rats Ahmed M-D Abdel-tawab, (Egypt), AM Hassan, AN-E Hassan Mon 253 Inhibitory effect of carbon monoxide-releasing molecule CORM-2 on TNF-α release from activated-RBL- 2H3 cells Masaaki Akagi, (Japan), Y Yasui, M Watanabe, A Maruyama, N Matsui, R Akagi Mon 254 5-(4-Methanesulphonyl-phenyl)-thyazole derivatives: new tools for chronic inflammatory disease biotherapy Melchor Alvarez de Mon, (Spain)F Ledo, E SanAntonio, E Sanz, R Corcostegui, A Berisa, V Rubio, ML Lucero, A Muñoz, A de-la-Hera Mon 255 Roles of COX/PGE/EP4 receptors in healing of indomethacin- induced small intestinal lesions in rats: Relation to VEGF expression Kikuko Amagase, (Japan), A Kojo, N Abe, R Hatazawa, M Tanigami, K Takeuchi Mon 256 Whole-body distribution and pharmacokinetics of radioiodinated fully humanized anti-VAP-1 antibody – a PET imaging study of rabbits Anu Autio, (Finland), PJ Vainio, A Mali, J Vainio, S Suilamo, V Oikonen, P Luoto, M Teräs, T Karhi, A Roivainen Mon 257 Analbuminemia: Cardiovascular function of endotoxemic rats Hermes Vieira Barbeiro, (Brazil), CB Lorigados, DF Barbeiro, S Catanozi, E Nakarandake, IT Velasco, FB Fusco, A dos Santos Filho, FG Soriano Mon 258 The effect of acute and chronic administration of Nevirapine on interleukin-2 in a rat model Zanelle Bekker, (South Africa), A Walubo, JB Du Plessis Mon 259 Apparent differences in pharmacokinetic performance between generic mycophenolate mofetil tablet formulations Darren Bentley, (UK), L Banken, R Robson Mon 260 Anti-inflammatory and antioxidant activities of an Indian medicinal plant, Emblica officinalis, in rodent models of inflammation Jagriti Bhatia, (India), M Golechha, DS Arya, F Tabassum Mon 261 Age-dependent effects of dexamethasone on hypoxic-ischemic brain edema Gábor Blazsó, (Hungary), M Pásztor, A Balogh, A Márki, G Dombi, G Falkay Mon 262 The differences of antiulcer activity of proton pump inhibitor (PPI) and H2-antagonist in diabetic rats Teresa Bobkiewicz-Kozlowska, (Poland), R Forjasz, M Nowaczyk Mon 263 Monitoring of azathioprine metabolites in pediatric patients with autoimmune hepatitis Roselyne Boulieu, (France), TMH Nguyen, C Le Gall, A Lachaux Mon 264 Searching for novel analgesic and anti-inflammatory analogs of anandamide Sumner Burstein, (USA), G Li, R Salmonsen, C McQuain, T Al, V Kattamuri Mon 265 Mitigation effect of esculentic acid on radiation-induced pneumonia and pulmonary fibrosis Yong-Bing Cao, (PR China), S-M Yang, Y-P Tian, M Zhang, L Zhang, K-Z Zhang, L-J Yin, B-R Zhang, R Howell, Y-Y Jiang, P Okunieff, L Zhang Mon 266 Remicade alleviates airway inflammation and hyperreactivity in asthmatic E3 rats Yong-Xiao Cao, (PR China), Y Cai, SM Lu, CB Xu, LO Cardell Monday 19 July ■ 13:00 - 14:00 ■ Poster Area 181
Page 1:
of basic and clinical pharmacology
Page 4 and 5:
Congress patron 2 HRH Crown Princes
Page 6 and 7:
Congress President Kim Brøsen Secr
Page 8 and 9:
General information Registration &
Page 10 and 11:
Banks, currency & credit cards The
Page 12 and 13:
Information to presenters ■ The a
Page 14 and 15:
Hotel Bella Center Copenhagen Groun
Page 16 and 17:
Programme at a glance Time Hall A2
Page 18 and 19:
16 General events General events Op
Page 20 and 21:
Programme outline Plenary lectures
Page 22 and 23:
FC10 Drugs for half the world: Paed
Page 24 and 25:
Tue 12:45 W13 Workshop: Novel perip
Page 26 and 27:
W01 Pharmacology of adrenoceptors:
Page 28 and 29:
W02 Symposium on advances in GI pha
Page 30 and 31:
W04 Symposium: Antioxidants as ther
Page 32 and 33:
Plenary lectures PL01 Plenary lectu
Page 34 and 35:
FC02 Transmembrane transport: Persp
Page 36 and 37:
FC04 Pharmacoepidemiology, current
Page 38 and 39:
FC06 The heart gone wrong: Stabiliz
Page 40 and 41:
FC09 Inflammation and immunopharmac
Page 42 and 43:
Page 44 and 45:
SS01 Sponsored symposium Sponsored
Page 46 and 47:
W06 Workshop. Effect of disease on
Page 48 and 49:
W08 Workshop. Identifying targets f
Page 50 and 51:
W10 Workshop. Innovative Medicines
Page 52 and 53:
FC01 Clinical pharmacology in the e
Page 54 and 55:
FC03 Ion channels in analgesia and
Page 56 and 57:
FC05 Translational science in the m
Page 58 and 59:
Page 60 and 61:
FC08 Development in the treatment o
Page 62 and 63:
Plenary lectures PL04 Plenary lectu
Page 64 and 65:
FC01 Clinical pharmacology in the e
Page 66 and 67:
FC03 Ion channels in analgesia and
Page 68 and 69:
FC05 Translational science in the m
Page 70 and 71:
FC07 Simulation and data modelling
Page 72 and 73:
FC09 Inflammation and immunopharmac
Page 74 and 75:
W12 Workshop. Experimental pain met
Page 76 and 77:
W14 Workshop. Translating the human
Page 78 and 79:
W15 Workshop. The IUPHAR initiative
Page 80 and 81:
W17 Workshop. Standards for PhD Edu
Page 82 and 83:
W19 Workshop. Influence of degenera
Page 84 and 85:
FC02 Transmembrane transport: Persp
Page 86 and 87:
FC04 Pharmacoepidemiology, current
Page 88 and 89:
Page 90 and 91:
FC08 Development in the treatment o
Page 92 and 93:
PL10 ASPET Plenary Lecture Chair: T
Page 94 and 95:
Page 96 and 97:
FC12 Ion channelopathies: New windo
Page 98 and 99:
FC14 Addiction and doping: Neurobio
Page 100 and 101:
FC17 New approaches and targets in
Page 102 and 103:
W04 Symposium: Antioxidants as ther
Page 104 and 105:
W21 Workshop. Inflammation - here,
Page 106 and 107:
W23 Workshop. Applying pharmacogeno
Page 108 and 109:
W25 Workshop. High science in the l
Page 110 and 111:
W27 Workshop. Approaches to medicin
Page 112 and 113:
FC11 G protein-coupled 7TM receptor
Page 114 and 115:
FC13 Maximising benefits and minimi
Page 116 and 117:
FC15 Endothelium in Health and dise
Page 118 and 119:
Page 120 and 121:
FC18 Nuclear receptor targets for t
Page 122 and 123:
PL16 Plenary Lecture Supported by a
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
FC15 Endothelium in Health and dise
Page 130 and 131:
Page 132 and 133: W28 Workshop. The Boehringer-Ingelh
Page 134 and 135: W30 Workshop. Is eNOS still a valid
Page 136 and 137: W32 Workshop. The good, the bad and
Page 138 and 139: W34 Workshop. State-of-the-art of b
Page 140 and 141: FC10 Drugs for half the world: Pedi
Page 142 and 143: FC12 Ion channelopathies: New windo
Page 144 and 145: FC14 Addiction and doping: Neurobio
Page 146 and 147: FC16 Natural products: Past and fut
Page 148 and 149: FC18 Nuclear receptor targets for t
Page 150 and 151: PL22 Plenary Lecture Chair: Zhi-Bin
Page 152 and 153: FC11 G protein-coupled 7TM receptor
Page 154 and 155: FC13 Maximising benefits and minimi
Page 156 and 157: FC15 Endothelium in health and dise
Page 158 and 159: FC17 New approaches and targets in
Page 160 and 161: 158
Page 162 and 163: FC01 Clinical pharmacology in the e
Page 166 and 167: FC02 Transmembrane transport: Persp
Page 168 and 169: FC03 Ion channels in analgesia and
Page 170 and 171: W12 Experimental pain methods in de
Page 172 and 173: FC04 Pharmacoepidemiology, current
Page 174 and 175: FC05 Translational science in the m
Page 178 and 179: FC06 The heart gone wrong; stabiliz
Page 180 and 181: FC07 Simulation and data modelling
Page 184 and 185: FC09 Inflammation and immunopharmac
Page 194 and 195: W03 Targeting TRP channels for pain
Page 196 and 197: W19 Influence of degeneration and r
Page 198 and 199: W19 Influence of degeneration and r
Page 200 and 201: W20 Pharmacology education for a su
Page 208 and 209: FC04 Pharmacoepidemiology, current
Page 214 and 215: FC06 The heart gone wrong; stabiliz
Page 216 and 217: FC07 Simulation and data modelling
Page 218 and 219: FC08 Developments in the treatment
Page 230 and 231: FC19 General session Tue 361 Analge
Page 232 and 233:
FC19 General session - Biologics Tu
Page 234 and 235:
FC19 General session - Haematology
Page 236 and 237:
FC19 General session - oncology Tue
Page 238 and 239:
FC19 General session - oncology Tue
Page 240 and 241:
FC19 General session - Toxicology T
Page 242 and 243:
Page 244 and 245:
W11 New opportunities in the pharma
Page 246 and 247:
W23 Applying pharmacogenomics (PGX)
Page 248 and 249:
Page 250 and 251:
Page 252 and 253:
Page 254 and 255:
FC12 Ion channelopathies: New windo
Page 256 and 257:
Page 258 and 259:
Page 260 and 261:
Page 262 and 263:
FC15 Endothelium in health and dise
Page 264 and 265:
Page 266 and 267:
Page 268 and 269:
W30 Is eNOS Still a valid therapeut
Page 270 and 271:
FC16 Natural products: Past and fut
Page 272 and 273:
Page 274 and 275:
Page 276 and 277:
Page 278 and 279:
Page 280 and 281:
W34 State-of-the-art of basic and c
Page 282 and 283:
Page 284 and 285:
Page 286 and 287:
Page 288 and 289:
Page 290 and 291:
Page 292 and 293:
Page 294 and 295:
W29 New horizons in therapeutic dru
Page 296 and 297:
Page 298 and 299:
Page 300 and 301:
Page 302 and 303:
Page 304 and 305:
Page 306 and 307:
Page 308 and 309:
Page 310 and 311:
Page 312 and 313:
Page 314 and 315:
FC18 Nuclear receptor targets for t
Page 316 and 317:
314 Index Name Paper ref. Name Pape
Page 318 and 319:
Page 320 and 321:
Page 322 and 323:
Page 324 and 325:
Page 326 and 327:
Page 328 and 329:
Page 330 and 331:
Page 332 and 333:
Page 334 and 335:
Page 336 and 337:
Page 338 and 339:
Page 340 and 341:
Page 342 and 343:
Page 344 and 345:
Page 346 and 347:
Page 348 and 349:
Page 350 and 351:
Page 352 and 353:
Page 354 and 355:
Page 356 and 357:
Page 358 and 359:
Page 360 and 361:
Page 362 and 363:
Page 364 and 365:
Page 366 and 367:
Page 368 and 369:
Page 370 and 371:
Page 372 and 373:
Page 374 and 375:
Page 376 and 377:
Page 378 and 379:
Page 380 and 381:
Page 382 and 383:
Page 384 and 385:
382 Notes Notes
Page 386:
Final Programme printed in Singapor
show all

Final Programme - iuphar

Create successful ePaper yourself

Delete template?

Save as template?